Olomoucine
(Synonyms: 2-(2'-羟基乙基氨基)-9-甲基-6-(苄基氨基)嘌呤) 目录号 : GC16520An inhibitor of cyclin-dependent kinases
Cas No.:101622-51-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Olomoucine is an ATP-competitive CDK inhibitor [1].
Cyclin-dependent kinases (CDKs) play important roles in the regulation of the cell division cycle and are therefore promising targets for cancer therapy [1].
Olomoucine is an ATP-competitive CDK inhibitor with IC50 values of 7, 7, 7, 3 and 25 μM against CDC2/cyclin B, Cdk2/cyclin A and Cdk2/cyclin E kinases, the brain CDK5/p35 kinase and the ERK1/p44 MAP kinase, respectively [1]. In metaphase-arrested Xenopus egg extracts, Olomoucine inhibited M-phase-promoting factor activity. Olomoucine provided an anti-mitotic reagent that might preferentially inhibit certain steps of the cell cycle [1]. In interleukin-2-stimulated T lymphocytes (CTLL-2 cells), Olomoucine inhibited DNA synthesis and caused Gl arrest [2].
In rats after after spinal cord injury (SCI), olomoucine attenuated astroglial proliferation and glial scar formation, decreased lesion cavity and mitigated functional deficits. In rats following SCI, olomoucine significantly decreased the spinal cord edema formation, suppressed microglial proliferation and attenuated production of proinflammatory cytokines in the traumatic spinal cord. Olomoucine also attenuated neuronal cell death [3].
References:
[1]. Vesel J, Havlicek L, Strnad M, et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem. 1994 Sep 1;224(2):771-86.
[2]. Abraham RT, Acquarone M, Andersen A, et al. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol Cell. 1995;83(2-3):105-20.
[3]. Tian DS, Xie MJ, Yu ZY, et al. Cell cycle inhibition attenuates microglia induced inflammatory response and alleviates neuronal cell death after spinal cord injury in rats. Brain Res. 2007 Mar 2;1135(1):177-85.
| Cas No. | 101622-51-9 | SDF | |
| 别名 | 2-(2'-羟基乙基氨基)-9-甲基-6-(苄基氨基)嘌呤 | ||
| 化学名 | 2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-ethanol | ||
| Canonical SMILES | OCCNc1nc(NCc2ccccc2)c2ncn(C)c2n1 | ||
| 分子式 | C15H18N6O | 分子量 | 298.3 |
| 溶解度 | ≤10mg/ml in ethanol;20mg/ml in DMSO;30mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3523 mL | 16.7616 mL | 33.5233 mL |
| 5 mM | 0.6705 mL | 3.3523 mL | 6.7047 mL |
| 10 mM | 0.3352 mL | 1.6762 mL | 3.3523 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。